The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $30.56

Today's change0.00 0.00%
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $30.56

Today's change0.00 0.00%
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc closed at (U.S.)$30.56.

Over the last five days, shares have gained 0.36% and 11.41% year to date. Shares have outperformed the S&P 500 by 50.62% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $30.56
  • High--
  • Low--
  • Bid / Ask(U.S.) $29.03 / (U.S.) $32.25
  • YTD % change+11.41%
  • Volume0
  • Average volume (10-day)1,485,001
  • Average volume (1-month)2,367,366
  • Average volume (3-month)2,405,214
  • 52-week range(U.S.) $8.00 to (U.S.) $63.73
  • Beta1.62
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.45
Updated March 27 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-4,930.18%

Sarepta Therapeutics Inc has a net profit margin of -4,930.18%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue5000
Total other revenue--------
Total revenue5000
Gross profit5------
Total cost of revenue0------
Total operating expense94576260
Selling / general / administrative23221821
Research & development71344439
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-88-57-62-60
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-88-57-62-60
Income after tax-88-57-62-60
Income tax, total--------
Net income-88-57-62-60
Total adjustments to net income--------
Net income before extra. items-88-57-62-60
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-88-57-62-60
Inc. avail. to common incl. extra. items-88-57-62-60
Diluted net income-88-57-62-60
Dilution adjustment--------
Diluted weighted average shares55484646
Diluted EPS excluding extraordinary itemsvalue per share-1.62-1.18-1.35-1.31
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-1.62-1.18-1.35-1.31